Hepatitis C News

In 1989, I was privileged to be part of a relatively small multicenter group that submitted a paper to The New England Journal of Medicine on non-A, non-B hepatitis. The paper focused on the use of interferon and, in the final stages of preparation of our study for publication, serum testing showed that almost all the study patients had the newly described hepatitis C virus.

Looking Back at ‘Your Guide to the Age After Interferon’

Results from a national survey showed that hepatitis C prevalence was higher in the West and Appalachian states between 2013 and 2016 compared with other areas, as reported in JAMA Network Open.

Every year, Healio Gastroenterology and Liver Disease meets with hepatology and gastroenterology experts to discuss their presentations on the latest research data, therapeutic updates, and recent advocacy programs.

Extrahepatic cancer was more common in patients with hepatitis C and was the leading cause of death in patients who achieved sustained virologic response compared with the general population, according to results of a French cohort study.

This year at The Liver Meeting, data presented on hepatitis C treatment highlighted continued significantly positive outcomes from direct-acting antiviral therapy, reduced rates of hepatocellular carcinoma, and improved outreach and screening techniques.

Sovaldi-based therapy was safe and effective in as short as 8 weeks for treating hepatitis C in patients with cancer and may induce remission of non-Hodgkin’s lymphoma, according to a recently published study.

Treatment with either pegylated interferon with ribavirin or direct-acting antivirals for hepatitis C correlated with a significantly lower risk for cardiovascular disease, especially among patients who achieved sustained virologic response, according to a study published in Gastroenterology.

Mavyret demonstrated 97% sustained virologic response in a large, real-world cohort of patients with hepatitis C over an 8-week course and extended 12-week to 16-week courses, according to recently published data.

The Medicines Patent Pool signed a royalty-free license agreement with AbbVie to enable quality-assured manufacturers to develop and sell generic medicines including Mavyret, according to a press release.